| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3609 | 2010 |
| An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 DR Owen, CMN Allerton, AS Anderson, L Aschenbrenner, M Avery, ... Science 374 (6575), 1586-1593, 2021 | 1612 | 2021 |
| Arachidonic Acid Oxygenation by COX-1 and COX-2: Mechanisms of Catalysis and Inhibition* 210 LJ Marnett, SW Rowlinson, DC Goodwin, AS Kalgutkar, CA Lanzo Journal of Biological Chemistry 274 (33), 22903-22906, 1999 | 713 | 1999 |
| Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical … AF Stepan, DP Walker, J Bauman, DA Price, TA Baillie, AS Kalgutkar, ... Chemical research in toxicology 24 (9), 1345-1410, 2011 | 706 | 2011 |
| A comprehensive listing of bioactivation pathways of organic functional groups AS Kalgutkar, I Gardner, RS Obach, CL Shaffer, E Callegari, KR Henne, ... Current drug metabolism 6 (3), 161-225, 2005 | 706 | 2005 |
| Biotransformation reactions of five-membered aromatic heterocyclic rings DK Dalvie, AS Kalgutkar, SC Khojasteh-Bakht, RS Obach, JP O'Donnell Chemical research in toxicology 15 (3), 269-299, 2002 | 592 | 2002 |
| Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors AS Kalgutkar, AB Marnett, BC Crews, RP Remmel, LJ Marnett Journal of medicinal chemistry 43 (15), 2860-2870, 2000 | 464 | 2000 |
| On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds TR White, CM Renzelman, AC Rand, T Rezai, CM McEwen, VM Gelev, ... Nature chemical biology 7 (11), 810-817, 2011 | 413 | 2011 |
| A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385 SW Rowlinson, JR Kiefer, JJ Prusakiewicz, JL Pawlitz, KR Kozak, ... Journal of Biological Chemistry 278 (46), 45763-45769, 2003 | 413 | 2003 |
| Aspirin-like molecules that covalently inactivate cyclooxygenase-2 AS Kalgutkar, BC Crews, SW Rowlinson, C Garner, K Seibert, LJ Marnett Science 280 (5367), 1268-1270, 1998 | 369 | 1998 |
| Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors AS Kalgutkar, BC Crews, SW Rowlinson, AB Marnett, KR Kozak, ... Proceedings of the National Academy of Sciences 97 (2), 925-930, 2000 | 348 | 2000 |
| Cyclooxygenase 2 inhibitors: discovery, selectivity and the future LJ Marnett, AS Kalgutkar Trends in pharmacological sciences 20 (11), 465-469, 1999 | 340 | 1999 |
| Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and … AS Kalgutkar, RS Obach, TS Maurer Current drug metabolism 8 (5), 407-447, 2007 | 274 | 2007 |
| Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human primates and mice EC Cokorinos, J Delmore, AR Reyes, B Albuquerque, R Kjøbsted, ... Cell metabolism 25 (5), 1147-1159. e10, 2017 | 264 | 2017 |
| Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors AS Kalgutkar, DK Dalvie, N Castagnoli, TJ Taylor Chemical research in toxicology 14 (9), 1139-1162, 2001 | 259 | 2001 |
| Minimising the potential for metabolic activation in drug discovery AS Kalgutkar, JR Soglia Expert opinion on drug metabolism & toxicology 1 (1), 91-142, 2005 | 253 | 2005 |
| Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential … DG Wishka, DP Walker, KM Yates, SC Reitz, S Jia, JK Myers, KL Olson, ... Journal of medicinal chemistry 49 (14), 4425-4436, 2006 | 244 | 2006 |
| Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of … RS Obach, AS Kalgutkar, JR Soglia, SX Zhao Chemical research in toxicology 21 (9), 1814-1822, 2008 | 229 | 2008 |
| Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure–activity relationships and discovery strategies to mitigate drug–drug interaction risks STM Orr, SL Ripp, TE Ballard, JL Henderson, DO Scott, RS Obach, H Sun, ... Journal of medicinal chemistry 55 (11), 4896-4933, 2012 | 223 | 2012 |
| Drug discovery for a new generation of covalent drugs AS Kalgutkar, DK Dalvie Expert opinion on drug discovery 7 (7), 561-581, 2012 | 191 | 2012 |